Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ieq Capital LLC

Ieq Capital LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 3,838 shares of the biopharmaceutical company’s stock after selling 1,496 shares during the quarter. Ieq Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $2,734,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Private Advisor Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.0% in the 3rd quarter. Private Advisor Group LLC now owns 5,361 shares of the biopharmaceutical company’s stock worth $5,635,000 after buying an additional 303 shares in the last quarter. Silver Oak Securities Incorporated grew its holdings in Regeneron Pharmaceuticals by 523.5% during the third quarter. Silver Oak Securities Incorporated now owns 929 shares of the biopharmaceutical company’s stock worth $969,000 after acquiring an additional 780 shares during the period. Ballentine Partners LLC raised its position in Regeneron Pharmaceuticals by 4.9% in the third quarter. Ballentine Partners LLC now owns 1,062 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 50 shares in the last quarter. Elwood & Goetz Wealth Advisory Group LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $517,000. Finally, Allworth Financial LP boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. Allworth Financial LP now owns 709 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 48 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.6 %

Regeneron Pharmaceuticals stock opened at $700.33 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $76.56 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08. The company’s fifty day simple moving average is $699.40 and its 200-day simple moving average is $882.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on REGN shares. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Finally, Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.